Health Canada
Symbol of the Government of Canada

Common menu bar links

Science and Research

ARCHIVED - Summary of Expertise, Experience, and Affiliations and Interests - Science Advisory Board

Warning This content was archived on June 24 2013.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.


The following table summarizes the information about expertise, experience, and affiliations and interests relevant to the Science Advisory Board mandate declared by board members. Health Canada considered these declarations as part of the appointment process.

This summary is available as part of Health Canada's commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each committee meeting, the Science Advisory Board Chair and executive secretary assess each member's affiliations and interests, including direct financial interests, as they may apply to agenda items. Based on this review, they will decide, if necessary, to limit a member's participation in all or part of the meeting agenda, and will inform the member of this decision. As well, on receipt of the meeting agenda, members are expected to review their own affiliations and interests against agenda items and advise the Chair and secretariat if they see a potential cause for concern regarding the integrity and objectivity of their participation.

Members are expected to report promptly any changes in their circumstances as reported on the Affiliations and Interests Declaration Form to the secretariat and the Chair of the advisory body. Health Canada also asks members to review their affiliations and interests declaration on an annual basis.

In accordance with sections 3.2 to 3.6 of the Health Canada Policy on External Advisory Bodies, a person with a direct financial interest in a matter on the advisory body agenda may not participate in discussions with respect to that item, but they may participate in discussions regarding policy, management, or program development as they relate to the mandate of the advisory body.

Indicated Sector/Perspective and Expertise/Experience

A variety of perspectives within the Board will be sought to ensure that the advice the Department and the Agency receives is comprehensive. Members of the Board will include but are not limited to the following:

  • scientists, researchers, academics, and individuals with expertise, knowledge, and experience relevant to the mandates of the Department and the Agency, i.e., Aboriginal health;
  • health professionals, including those with practical and clinical experience;
  • those with practical experience or expertise in relevant consumer or patient issues;
  • industry.

The members of the Board are individuals external to the federal government who have knowledge, experience and expertise relevant to the mandates of Health Canada and PHAC such as in the following areas:

  • Epidemiology and biostatistics;
  • Chronic Illness - health promotion;
  • Pharmaco-epidemiology;
  • Gene therapeutics and biological chemistry;
  • Cancer research and risk factors;
  • Medical Anthropology;
  • Aboriginal Health;
  • Toxicology Risk Assessment;
  • Nutrition;
  • Epidemiology.
  1. Direct financial interests

    Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares, or bonds that relate to the mandate of the advisory body.

  2. Indirect financial interests
    1. Within the past five years, payment from the regulated industry for work done or being done, including past employment, contracts, or consulting; or financial support, including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria.1
    2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by a party with an interest in the mandate of the advisory body.2
    3. Within the last three years, grants or other funding from a party with an interest in the mandate of the advisory body to any of the organizations where you are currently employed or participate in internal decision making.3
  3. Intellectual interests
    1. Within the last five years, any formal advice or opinion to industry, a government organization, or a non-government organization.
    2. Within the last five years, any published or publicly stated point of view.
    3. Current professional or volunteer affiliations, such as membership of professional societies, lobbying, public interest, or advocacy groups.
  4. Other

    Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation.

Name and
Indicated Sector/
Perspective and Expertise
Summary of Responses
Renaldo Battista Health Policy and Management Health Technology Assessment 1a. No 2a. Yes 2b. No 2c. No 3a. Yes 3b. Yes 3c. No 4a. No
Comments: Dr. Battista is a Member of the Board of Directors for the Canadian Agency for Drugs and Technologies in Health, a Member of the Board of Directors for Research Canada and a Member of the Priority Committee on Health Services Research, the Institute of Genetics, and the Canadian Institutes for Health Research. He is a Consultant for ad-hoc committees on risk management (February 2010), and on Health Technology Assessment (March 2010), Health Canada and the ad-hoc committee on the future of innovation (2009-10), Pfizer Canada (honorarium).
Stephen Bornstein Government and
Canadian Health Policy
1a. No 2a. No 2b. No 2c. No 3a. No 3b. No 3c. No 4a. No
Comments: None
Ahmed El-Sohemy Nutritional Sciences (molecular biology major)
1a. No 2a. Yes 2b. No 2c. No 3a. No 3b. No 3c. Yes 4a. No
Comments: Dr. El-Sohemy has received a research grant from the Dairy Farmers of Canada and has delivered a speech to the Canadian Coffee Association. He currently serves on the Board of Directors for the Natural Health Products Research Society of Canada.
Claire Franklin Toxicology Risk Assessment 1a. No 2a. No 2b. No 2c. No 3a. No 3b. No 3c. No 4a. No
Comments: None
Jack Gauldie Biological Chemistry; Gene Therapeutics 1a. Yes 2a. Yes 2b. Yes 2c. Yes 3a. Yes 3b. No 3c. Yes 4a. No
Comments: Dr. Gauldie has received research grants and contracts from: GlaxoSmithKline, Medimmune, Intermune, Defyrus, Transtechphamra. Shareholder: Defyrus Inc, Vistagen Therapeutics Inc. He has given presentations at GlaxoSmithKline United Kingdom Pulmonary Conferences (2009 to present) and is involved in various research grants and contracts through McMaster University. He is an advisor to the Canadian Institutes for Health Research's Institute for Infection and Immunity, and to the Ontario Research Fund, and is the Medical Research Centre United Kingdom Centre for Inflammation Research Edinburgh Chair. He has published over 350 scientific manuscripts on pathogens of particular diseases and is a Fellow of the Royal Society of Canada.
Susan Kennedy Pathology, Epidemiology
Environmental Health and Health Care
1a. No 2a. No 2b. No 2c. Yes 3a. Yes 3b. Yes 3c. No 4a. No
Comments: Dr. Kennedy has received grant funding from the Canadian Institutes of Health Research, Networks of Centres of Excellence, WorksafeBC and British Columbia Ferry Corporation. She is a former member of the Environment Canada Science Advisory Board (2001 to 2005). Recent publications have been on respiratory epidemiology and gender influences in occupational exposure assessment for respiratory disease.
Chris Loomis Pharmacology & Toxicology
1a. No 2a. No 2b. No 2c. Yes 3a. No 3b. No 3c. No 4a. No
Comments: Dr. Loomis Oversees the management of clinical trials undertaken by clinical professors in the Faculty of Medicine at Memorial University.
Renee Lyons Counselling Psychology, Health studies - coping and adaptation in chronic disease

Chronic Illness - health promotion

1a. No 2a. Yes 2b. No 2c. No 3a. Yes 3b. Yes 3c. No 4a. No
Comments: Dr. Lyons has received research awards from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Her publications have been on subjects such as Conservation of Resources Theory and Knowledge in health systems and disability, chronic illness, and relationship functioning.
John O'Neil Medical Anthropology
Aboriginal Health
1a. No 2a. No 2b. No 2c. No 3a. Yes 3b. Yes 3c. Yes 4a. No
Comments: Comments: Dr. O'Neil is a Board Member on the Michael Smith Foundation for Health Research (British Columbia) and a member of the Advisory Council for National Collaborating Centre for Aboriginal Health (Public Health Agency of Canada).
Yola Moride Epidemiology Biostatistics
1a. No 2a. Yes 2b. Yes 2c. Yes 3a. Yes 3b. Yes 3c. Yes 4a. No
Comments: Dr. Moride has carried out consultancies for industry and regulatory authorities since 2003. She holds memberships on Data Safety Monitoring Boards and science advisory boards providing advice on: Expert Safety Assessment; Risk management planning; Drug utilization studies; and teaching.

Dr. Moride attended the International Society of Pharmacoepidemiology's annual meeting in 2011. Her research at the University of Montreal Hospital Centre, is partially funded by the pharmaceutical industry and she is the President of YolaRx Consultants inc., a consulting firm for the pharmaceutical industry and regulatory agencies.

She is a member of The Expert Panel on Caffeinated Drinks, 2008-2009 (Expert Assessor - Health Canada; 2008), the Reference group for the development of the regulatory frameworks that will be required to align with a modernized Food and Drugs Act under Bill C51(2004-present); the Independent data monitoring board for Erythropoeitin (Eprex) (Johnson & Johnson, USA; 2011- present); RM Global Advisory Board for Teriflunomide (Sanofi-aventis; 2010-present) and the Real-world Evaluation Global Advisory Board (Sanofi-aventis France, 2008) and the Standing Committee on Health (House of Commons); the International Society of Pharmacovigilance and of the International Society of Pharmacoepidemiology (former President 2007-2008).

Marie-Élise Parent Nutrition, Epidemiology
Cancer Risk Factors
1a. No 2a. Yes 2b. No 2c. No 3a. No 3b. Yes 3c. Yes 4a. No
Comments: Dr. Parent has had research contracts with Health Canada studying Occupational exposure assessment for lung cancer study (2006-07), Diesel and lung cancer (2006), and the translation of lists of occupational chemicals (2006). She sits on the Board of Directors of the Canadian Cancer Society as Director-at-Large-Research, as well as on the Boards of the Canadian Society for Epidemiology and Biostatistics and of the Institut national de la recherche scientifique. She has published several articles in high-profile peer-review journals in the area of cancer epidemiology.
Lori Sheremeta Health Law and Ethics

1a. No 2a. Yes 2b. Yes 2c. No 3a. Yes 3b. Yes 3c. Yes 4a. Yes
Comments: Ms. Sheremeta has had contracts with Health Canada and the Canadian Biotechnology Advisory Board (2001-2006). She has received funding for research from the National Institute for Nanotechnology (NINT), Government of Alberta, and the Government of Canada. She is a unpaid member of the Council of Canadian Academies, the Expert Panel on Nanotechnology. Published articles include: Expert Panel on Nanotechnology, "Small is Different: A Science Perspective on the Regulatory Challenges of the Nanoscale" Council of Canadian Academies, September 2008; "Public Meets Private: Challenges for Informed Consent and Umbilical Cord Blood Banking in Canada" (2007) 15:2 Health Law Review; "Somatic Cell Nuclear Transfer - How Science Outpaces the Law" (2003) 21 Nat. Biotech. 969.

Ms. Sheremeta is a member of the Law Society of British Columbia; "One Match" Canadian Blood Services Science Advisory Board; Hereditary Breast and Ovarian Cancer Society of Alberta Science Advisory Board.

Jacques Simard Physiology,
Molecular Endocrin-
ology, Biology
Genomics / Cancer Research
1a. No 2a. Yes 2b. No 2c. Yes 3a. Yes 3b. Yes 3c. Yes 4a. Yes
Comments: Dr. Simard received Director's fees from the Fonds de solidarité FTQ New Economy sector council, a major investor in venture capital in the field of life sciences in Canada and from BRCA1 and BRCA2: Past, Present and Future. 3rd International Symposium on Hereditary Breast and Ovarian Cancer: BRCA: 15 Years of Progress (2009).

He is the Chair of the Genome Canada Science and Industry Advisory Committee (July 2010-present) and a member of the Fonds de solidarité FTQ New Economy sector Council (2009-present); Association francophone pour le savoir (ACFAS); Canadian Society for Clinical Investigation; Club de recherches cliniques du Québec; and the Canadian Academy of Health Sciences.

Dr. Simard is a past member of the Genome Canada Board of Directors (2005-2010); Ad-hoc committee of the Génome Québec Board of Directors for the development of the brief presented to the Groupe-conseil pour l'actualisation de la Stratégie québécoise de la recherche et de l'innovation (2009); the evaluation committee of the Ontario Research Fund - Research Excellence Round 5 Genomics Panel (2010-2011); and the Technological Investments Sector Council (1999-2009) of the Fonds de solidarité FTQ.

He was a guest speaker at several Canadian and international conventions and conferences.

Lorne Tyrrell Pharmacology
Microbiology - Immunology
1a. No 2a. Yes 2b. No 2c. No 3a. No 3b. No 3c. Yes 4a. No
Comments: Dr. Tyrrell received research support from GlaxoSmithKline (research contract with CIHR); an endowment from GlaxoSmithKline to the University of Alberta's Li Ka Shing Institute of Virology. He is a Director on the Board of a publically traded company: Burcon (receives no government funding) and is Chairman of the Board of the Gairdner Foundation; Health Quality Council of Alberta; Institute of Health Economics of Alberta. He is a member of the Science Advisory Council of the Canadian Institute for Advanced Research; and Canadian Medical Hall of Fame.
Annalee Yassi Health Science, Occupational Health and Safety, Community Health, Occupational and Environmental Health, Health Promotion and Prevention 1a. No 2a. No 2b. No 2c. No 3a. Yes 3b. Yes 3c. Yes 4a. No
Comments: Dr. Yassi was the lead consultant for the World Health Organization in developing guidelines on how to improve access of health workers to prevention, treatment and care for HIV and Tuberculosis. She advised the Pan American Health Organization in preparing health workers in Trinidad and Tobago for a biological incident or pandemic. Her numerous publications related to Health Canada's mandate, include: "Assuming our global responsibility: Improving working conditions for healthcare workers globally "- Open Medicine, 2009 and "Which approaches to talking neglected tropical diseases show promise?" - PloS Medicine, 2010. Dr. Yassi is also Chair of the Scientific Committee for Healthcare of the International Commission on Occupational Health (volunteer - professional association).

1 other than from present employer

2 other than from present employer, over $1,000

3 "participate in internal decision making" as a board member or executive or non-executive director